Multiple Sclerosis, Secondary Progressive
35
7
11
15
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.7%
2 terminated out of 35 trials
88.2%
+1.7% vs benchmark
9%
3 trials in Phase 3/4
20%
3 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (35)
Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis
Intermittent Hypoxia in Persons With Multiple Sclerosis
Motor Asymmetry in Progressive Multiple Sclerosis Patients
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
The Synergistic Effects of AIH and FES in Persons With MS
Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
The Effects of In-phase Bilateral Exercise in People with Progressive Multiple Sclerosis
Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
Exercise Effects in Multiple Sclerosis
MS-ResearchBiomarkerS
Phase II Clinical Trial of OCH-NCNP1
Novel Imaging Markers in SPMS
Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis